Published in Blood on July 03, 2007
CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell (2009) 5.30
Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA (2010) 3.25
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood (2012) 2.65
Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol (2011) 2.52
Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci U S A (2011) 1.71
The hematopoietic stem cell niche--home for friend and foe? Cytometry B Clin Cytom (2012) 1.70
Right on target: eradicating leukemic stem cells. Trends Mol Med (2007) 1.49
Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood (2012) 1.36
Recent advances in acute myeloid leukemia stem cell biology. Haematologica (2012) 1.25
IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood (2015) 1.14
Mechanisms of resistance to FLT3 inhibitors. Drug Resist Updat (2009) 1.05
Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica (2009) 1.03
Concise review: Leukemia stem cells in personalized medicine. Stem Cells (2014) 1.02
C-type lectin-like receptors of the dectin-1 cluster: ligands and signaling pathways. Int Rev Immunol (2013) 0.98
Humanized hemato-lymphoid system mice. Haematologica (2016) 0.98
Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? J Hematol Oncol (2015) 0.96
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry A (2015) 0.95
Inhibitory C-type lectin receptors in myeloid cells. Immunol Lett (2010) 0.94
Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS One (2014) 0.94
Concise review: Cancer stem cells and minimal residual disease. Stem Cells (2012) 0.94
In vivo expansion of co-transplanted T cells impacts on tumor re-initiating activity of human acute myeloid leukemia in NSG mice. PLoS One (2013) 0.93
Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future. Bone Marrow Transplant (2014) 0.93
Investigating molecular profiles of ovarian cancer: an update on cancer stem cells. J Cancer (2014) 0.90
A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer (2014) 0.89
A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting. MAbs (2012) 0.87
Acute myelogenous leukemia stem cells: from Bench to Bedside. Cancer Lett (2012) 0.86
Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. Haematologica (2014) 0.86
Multi-parameter fluorescence-activated cell sorting and analysis of stem and progenitor cells in myeloid malignancies. Best Pract Res Clin Haematol (2010) 0.86
Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells. PLoS One (2013) 0.85
Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia. World J Stem Cells (2014) 0.85
Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia. Angew Chem Int Ed Engl (2014) 0.84
FISH+CD34+CD38- cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome. J Hematol Oncol (2013) 0.84
Targeting myelogenous leukemia stem cells: role of the circulation. Front Oncol (2012) 0.84
Overexpression of IL-3Rα on CD34+CD38- stem cells defines leukemia-initiating cells in Fanconi anemia AML. Blood (2011) 0.84
Therapeutics formulated to target cancer stem cells: Is it in our future? Cancer Cell Int (2011) 0.83
Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells. Nanomedicine (2011) 0.83
Chemotherapy targeting cancer stem cells. Am J Cancer Res (2015) 0.83
Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity. Exp Hematol (2013) 0.83
CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia. Cell Stem Cell (2015) 0.82
Therapies targeting cancer stem cells: Current trends and future challenges. World J Stem Cells (2015) 0.82
Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells. Semin Hematol (2015) 0.80
Can immunotherapy specifically target acute myeloid leukemic stem cells? Oncoimmunology (2013) 0.79
A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia. Leukemia (2015) 0.79
OCT4 pseudogenes present in human leukemia cells. Clin Exp Med (2011) 0.79
The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients. Int J Cancer (2015) 0.79
Direct confirmation of quiescence of CD34+CD38- leukemia stem cell populations using single cell culture, their molecular signature and clinicopathological implications. BMC Cancer (2015) 0.78
Re-evaluation of various molecular targets located on CD34(+)CD38(-)Lin(-) leukemia stem cells and other cell subsets in pediatric acute myeloid leukemia. Oncol Lett (2015) 0.78
Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells. J Hematol Oncol (2016) 0.78
Is minimal residual disease monitoring clinically relevant in adults with acute myelogenous leukemia? Curr Hematol Malig Rep (2013) 0.78
Cancer stem cells in haematological malignancies. Contemp Oncol (Pozn) (2015) 0.77
The C-type lectin-like receptors of Dectin-1 cluster in natural killer gene complex. Glycoconj J (2012) 0.77
Reactive oxygen species in eradicating acute myeloid leukemic stem cells. Stem Cell Investig (2014) 0.77
Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities. World J Stem Cells (2016) 0.76
Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1. Oncotarget (2016) 0.75
Acute myeloid leukemia targets for bispecific antibodies. Blood Cancer J (2017) 0.75
Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin. Nanomedicine (Lond) (2014) 0.75
An anti-CD3 / anti-CLL-1 Bispecific Antibody for the treatment of Acute Myeloid Leukemia. Blood (2016) 0.75
Biology and relevance of human acute myeloid leukemia stem cells. Blood (2017) 0.75
Unravelling the relevance of CLEC12A as a cancer stem cell marker in myelodysplastic syndrome. Br J Haematol (2016) 0.75
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications. Mediterr J Hematol Infect Dis (2016) 0.75
Understanding of leukemic stem cells and their clinical implications. Mol Cancer (2017) 0.75
Translating leukemia stem cells into the clinical setting: Harmonizing the heterogeneity. Exp Hematol (2016) 0.75
DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders. Front Oncol (2016) 0.75
Specific Depletion of Leukemic Stem Cells: Can MicroRNAs Make the Difference? Cancers (Basel) (2017) 0.75
Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress? J Clin Med (2017) 0.75
Recent developments in immunotherapy of acute myeloid leukemia. J Hematol Oncol (2017) 0.75
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. Nat Immunol (2008) 4.94
High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med (2009) 4.90
Cytarabine dose for acute myeloid leukemia. N Engl J Med (2011) 4.15
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol (2012) 3.93
89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med (2003) 3.26
Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol (2005) 3.15
Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res (2006) 2.71
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood (2010) 2.42
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol (2013) 2.22
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood (2011) 2.12
Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med (2009) 2.12
Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc (2010) 2.09
Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med (2008) 2.08
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol (2012) 2.05
p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging (2009) 2.01
High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood (2002) 2.01
The adverse prognosis for acute myeloid leukemia patients with superior autologous stem cell mobilization. Leuk Res (2012) 1.95
High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res (2005) 1.94
Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood (2007) 1.92
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol (2010) 1.81
Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities. Haematologica (2005) 1.75
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood (2011) 1.75
Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis. Proc Natl Acad Sci U S A (2006) 1.71
Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med (2009) 1.68
Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood (2012) 1.67
Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med (2006) 1.62
Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging (2006) 1.58
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol (2012) 1.58
Adherence and patients' experiences with the use of oral anticancer agents. Acta Oncol (2013) 1.56
(89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med (2005) 1.56
Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med (2003) 1.56
Nanocolloidal albumin-IRDye 800CW: a near-infrared fluorescent tracer with optimal retention in the sentinel lymph node. Eur J Nucl Med Mol Imaging (2012) 1.49
Long-term follow-up of tandem autologous stem-cell transplantation in multiple myeloma. J Clin Oncol (2010) 1.48
Basic principles, applications in oncology and improved selectivity of photodynamic therapy. Anticancer Res (2003) 1.48
Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival. Leuk Lymphoma (2008) 1.46
A threshold of 10% for myeloperoxidase by flow cytometry is valid to classify acute leukemia of ambiguous and myeloid origin. Cytometry B Clin Cytom (2013) 1.41
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica (2009) 1.40
Neonatal porencephaly and adult stroke related to mutations in collagen IV A1. Ann Neurol (2006) 1.40
The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer. Radiother Oncol (2010) 1.40
Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging (2008) 1.36
Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. Mol Imaging (2012) 1.33
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica (2008) 1.33
High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood (2012) 1.32
C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res (2004) 1.32
Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood (2006) 1.31
Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm (2003) 1.31
Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. J Clin Oncol (2012) 1.30
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res (2006) 1.30
Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. Br J Haematol (2013) 1.28
The human cytomegalovirus-encoded chemokine receptor US28 promotes angiogenesis and tumor formation via cyclooxygenase-2. Cancer Res (2009) 1.28
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica (2013) 1.26
Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol Cancer Ther (2008) 1.24
89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med (2010) 1.23
Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy. J Clin Oncol (2010) 1.22
ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review. J Pathol (2003) 1.22
Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer (2010) 1.21
Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET. Eur J Nucl Med Mol Imaging (2012) 1.21
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica (2013) 1.19
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol (2013) 1.17
Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets. EJNMMI Res (2011) 1.16
A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int J Cancer (2011) 1.16
Identification of anti-repressor elements that confer high and stable protein production in mammalian cells. Nat Biotechnol (2003) 1.15
Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem Cells (2008) 1.14
Characterization of the human Ly-6 antigens, the newly annotated member Ly-6K included, as molecular markers for head-and-neck squamous cell carcinoma. Int J Cancer (2003) 1.12
Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood (2002) 1.11
The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood (2013) 1.11
Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res (2004) 1.11
PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors. J Nucl Med (2010) 1.11
¹⁸F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review. Cancer (2011) 1.09
Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood (2004) 1.08
Multicenter harmonization of 89Zr PET/CT performance. J Nucl Med (2013) 1.07
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood (2010) 1.07
Sequential organ failure predicts mortality of patients with a haematological malignancy needing intensive care. Eur J Haematol (2005) 1.07
Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy. Br J Haematol (2011) 1.06